27773526|t|An S116R Phosphorylation Site Mutation in Human Fibroblast Growth Factor-1 Differentially Affects Mitogenic and Glucose-Lowering Activities
27773526|a|Fibroblast growth factor-1 (FGF-1), a potent human mitogen and insulin sensitizer, signals through both tyrosine kinase receptor -mediated autocrine / paracrine pathways as well as a nuclear intracrine pathway. Phosphorylation of FGF-1 at serine 116 (S116) has been proposed to regulate intracrine signaling. Position S116 is located within a ∼17 amino acid C-terminal loop that contains a rich set of functional determinants including heparin ∖ heparan sulfate affinity, thiol reactivity, nuclear localization, pharmacokinetics, functional half-life, nuclear ligand affinity, stability, and structural dynamics. Mutational targeting of specific functionality in this region without perturbing other functional determinants is a design challenge. S116R is a non-phosphorylatable variant present in bovine FGF-1 and other members of the human FGF family. We show that the S116R mutation in human FGF-1 is accommodated with no perturbation of biophysical or structural properties, and is therefore an attractive mutation with which to elucidate the functional role of phosphorylation. Characterization of S116R shows reduction in NIH 3T3 fibroblast mitogenic stimulation, increase in fibroblast growth factor receptor-1c activation, and prolonged duration of glucose lowering in ob/ob hyperglycemic mice. A novel FGF-1 / fibroblast growth factor receptor-1c dimerization interaction combined with non-phosphorylatable intracrine signaling is hypothesized to be responsible for these observed functional effects.
27773526	3	29	S116R Phosphorylation Site	T087	C1519254
27773526	30	38	Mutation	T045	C0026882
27773526	42	47	Human	T016	C0086418
27773526	48	74	Fibroblast Growth Factor-1	T116,T123	C0079349
27773526	98	107	Mitogenic	T043	C1752930
27773526	112	139	Glucose-Lowering Activities	T033	C0860801
27773526	140	166	Fibroblast growth factor-1	T116,T123	C0079349
27773526	168	173	FGF-1	T116,T123	C0079349
27773526	185	190	human	T016	C0086418
27773526	191	198	mitogen	T116,T123	C0018284
27773526	203	210	insulin	T116,T121,T125	C0021641
27773526	223	230	signals	T044	C0037080
27773526	244	268	tyrosine kinase receptor	T116,T126,T192	C0206364
27773526	279	288	autocrine	T043	C0525010
27773526	291	309	paracrine pathways	UnknownType	C0678844
27773526	323	330	nuclear	T082	C0521447
27773526	331	349	intracrine pathway	T044	C1154545
27773526	351	366	Phosphorylation	T044	C0031715
27773526	370	375	FGF-1	T116,T123	C0079349
27773526	379	389	serine 116	T116,T121,T123	C0036720
27773526	391	395	S116	T116,T121,T123	C0036720
27773526	418	426	regulate	T044	C3158094
27773526	427	447	intracrine signaling	T044	C1154545
27773526	458	462	S116	T116,T121,T123	C0036720
27773526	487	513	amino acid C-terminal loop	T087	C1707271
27773526	542	565	functional determinants	T123	C0574031
27773526	576	583	heparin	T109,T121,T123	C0019134
27773526	586	601	heparan sulfate	T109,T123	C0019143
27773526	602	610	affinity	T070	C1510827
27773526	612	617	thiol	T109	C0038734
27773526	618	628	reactivity	T169	C0443286
27773526	630	650	nuclear localization	T087	C0525021
27773526	652	668	pharmacokinetics	T169	C0031328
27773526	670	680	functional	T169	C0205245
27773526	681	690	half-life	T079	C0018517
27773526	692	699	nuclear	T082	C0521447
27773526	700	706	ligand	T103	C0023688
27773526	707	715	affinity	T070	C1510827
27773526	717	726	stability	T080	C0205360
27773526	732	751	structural dynamics	T044	C0596957
27773526	753	763	Mutational	T045	C0026882
27773526	764	773	targeting	T169	C1521840
27773526	823	833	perturbing	T169	C0332453
27773526	840	863	functional determinants	T123	C0574031
27773526	887	892	S116R	T116,T121,T123	C0036720
27773526	898	918	non-phosphorylatable	T033	C0243095
27773526	919	926	variant	T080	C0205419
27773526	938	944	bovine	T015	C3667982
27773526	945	950	FGF-1	T116,T123	C0079349
27773526	976	981	human	T016	C0086418
27773526	982	992	FGF family	T116,T123	C0016026
27773526	1011	1025	S116R mutation	T045	C0026882
27773526	1029	1034	human	T016	C0086418
27773526	1035	1040	FGF-1	T116,T123	C0079349
27773526	1065	1077	perturbation	T169	C0332453
27773526	1081	1092	biophysical	T070	C2350452
27773526	1096	1106	structural	T085	C0026383
27773526	1139	1149	attractive	T080	C2346874
27773526	1150	1158	mutation	T045	C0026882
27773526	1187	1197	functional	T169	C0205245
27773526	1206	1221	phosphorylation	T044	C0031715
27773526	1223	1239	Characterization	T052	C1880022
27773526	1243	1248	S116R	T116,T121,T123	C0036720
27773526	1268	1275	NIH 3T3	T025	C1257739
27773526	1276	1286	fibroblast	T025	C0016030
27773526	1287	1308	mitogenic stimulation	T043	C1752930
27773526	1310	1318	increase	T169	C0442805
27773526	1322	1358	fibroblast growth factor receptor-1c	T116,T126,T192	C0170936
27773526	1359	1369	activation	T043	C1514758
27773526	1397	1413	glucose lowering	T033	C0860801
27773526	1417	1422	ob/ob	T047	C0028754
27773526	1423	1436	hyperglycemic	T047	C0020456
27773526	1437	1441	mice	T015	C0025929
27773526	1445	1450	novel	T080	C0205314
27773526	1451	1456	FGF-1	T116,T123	C0079349
27773526	1459	1495	fibroblast growth factor receptor-1c	T116,T126,T192	C0170936
27773526	1496	1508	dimerization	T070	C0376525
27773526	1509	1520	interaction	T169	C1704675
27773526	1521	1529	combined	T080	C0205195
27773526	1535	1555	non-phosphorylatable	T033	C0243095
27773526	1556	1576	intracrine signaling	T044	C1154545
27773526	1621	1629	observed	T169	C1441672